The short version
Only one company currently supplies this market — there is no backup if it stumbles.
Market view
epcoritamab-bysp · Injection
1 marketed package NDCs · 1 active manufacturer
Same drug class
Other molecules FDA puts in Bispecific CD20-directed CD3 T Cell Engager, with whether each is in shortage right now. Same class is not the same drug — substitution is a clinical decision, and this is a supply picture, not a recommendation.
Common questions
- Is Epcoritamab-bysp in shortage right now?
- No. FDA does not currently list Epcoritamab-bysp in shortage. This page is rebuilt every morning from FDA's shortage database, so a new posting appears here the day it is published.
- Who makes Epcoritamab-bysp?
- 2 companies have marketed Epcoritamab-bysp in the last 30 days, according to the FDA NDC Directory. That is a thin market — if one stops making it, supply is at risk quickly. Every manufacturer and package is listed on this page.
All marketed products
Expand a strength to see its dosage forms, then package sizes, then each manufacturer and NDC. Click an NDC for its full detail page.